LUNDBECK'S NEW MIGRAINE DRUG VYEPTI APPROVED BY FDA
by John G. Baresky on 02/23/20
Vyepti: Lundbeck new product launch expected in April 2020 for
Lundbeck
Lundbeck (OTCMKTS: HLUYY) has received
FDA approval for its migraine therapy product Vyepti (eptinezumab-jjmr). Vyepti
is indicated for the preventive treatment of migraine in adults.
Vyepti is an infused pharmaceutical therapy. Lundbeck anticipates the product being
available to prescribers and patients in April 2020.
Vyepti is an early result of Lundbeck’s
purchase of Alder
The product originated from the product pipeline of
Alder Pharmaceuticals. Lundbeck acquired Alder for about $2 billion in
2019.
Vyepti is an intravenous (IV) mAb therapy
The recommended dose of Vyepti is 100 mg every 3 months and it is noted some patients may benefit from a dose of 300 mg. Vyepti is a humanized monoclonal antibody (mAb) that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.
Vyepti will be up against strong competition from Aimovig (Amgen and Novartis), Ajovy (Teva), Emgality (Eli Lilly) and other migraine products.
Lundbeck is a global pharmaceutical
company
Headquartered in Copenhagen, Denmark
with a U.S. base located in Deerfield, Illinois (a Chicago suburb) Lundbeck is
centered on brain and psychiatric pharmaceutical therapies.
Some of Lundbeck's best-known products include:
·
Abilify (aripiprazole)
·
Northera (droxidopa)_
·
Onfi (clobazam)
·
Rexulti (brexpiprazole)
·
Sabril (vigabatrin)
·
Trintellix (vortioxetine)
·
Xenazine (tetrabenazine)
